Dr Kate Vandyke

Research Fellow (B) (with PhD)

School of Biomedicine

Faculty of Health and Medical Sciences

Eligible to supervise Masters and PhD - email supervisor to discuss availability.

I am currently a Cancer Council SA Beat Cancer Early Career Research Fellow and co-lead of the Myeloma Research Laboratory, Faculty of Health and Medical Sciences, University of Adelaide, based at the South Australian Health and Medical Research Institute (SAHMRI), Precision Medicine Theme.

My research interests involve elucidating the molecular and cellular mechanisms responsible for the disease progression in the bone marrow cancer multiple myeloma. Myeloma is the second most common blood cancer, responsible for over 100,000 deaths per year, world-wide. While significant advances in myeloma treatment over the past decade have greatly improved survival rates for multiple myeloma, almost all patients eventually relapse and succumb to their disease. My studies are primarily aimed at identifying those patients that do very poorly, surviving less than 2 years, and identifying tailored treatments for this group of patients.https://aurora.adelaide.edu.au/userprofile.html?uid=3778&em=true#

My Research
Career
Publications
Grants and Funding
Supervision
Professional Activities
Contact

My current research interests involve elucidating the molecular and cellular mechanisms responsible for the disease progression in the bone marrow cancer multiple myeloma. Myeloma is the second most common blood cancer, responsible for over 100,000 deaths per year, world-wide. While significant advances in myeloma treatment over the past decade have greatly improved survival rates for multiple myeloma, almost all patients eventually relapse and succumb to their disease. My studies are primarily aimed at identifying those patients that do very poorly, surviving less than 2 years, and identifying tailored treatments for this group of patients.

https://health.adelaide.edu.au/florey120anniversary/our-current-health-leaders/decoding-myeloma-cancer

Current projects include:

Defining major cellular and molecular mechanisms that drive tumour dissemination in multiple myeloma
Identifying how changes to the myeloma bone marrow microenvironment drive disease progression for MGUS and smouldering myeloma to multiple myeloma
Identification of novel serum biomarkers that enable the identification of high-risk MGUS, smouldering myeloma and multiple myeloma patients
Using novel drug delivery strategies to increase tumour-specific drug uptake and decrease off-target side-effects in multiple myeloma
Identification of novel therapeutic targets for the treatment of high-risk multiple myeloma

Appointments

Date	Position	Institution name
2020 - ongoing	Senior research fellow	South Australian Health and Medical Research Institute
2018 - ongoing	Beat Cancer Early Career Research Fellow	University of Adelaide, Adelaide
2017 - 2018	Post-doctoral Research Scientist	University of Adelaide, Adelaide
2013 - 2016	Mary Overton Early Career Research Fellow	SA Pathology
2012 - 2018	Affiliate Lecturer	University of Adelaide
2012 - 2013	Multiple Myeloma Research Foundation Research Fellow	SA Pathology
2010 - 2012	Post-doctoral Research Scientist	SA Pathology
2007 - 2010	Technical assistant (part time)	SA Pathology
2005 - 2006	Research Assistant	Prince of Wales Hospital

Education

Date Institution name Country Title

2007 - 2010 University of Adelaide Australia PhD

2000 - 2004 University of New South Wales Australia BMedSci (Hons)
Research Interests

Cancer Cell Biology Cancer Therapy Haematological Tumours Cancer Biology and Clinical Oncology

Date	Institution name	Country	Title
2007 - 2010	University of Adelaide	Australia	PhD
2000 - 2004	University of New South Wales	Australia	BMedSci (Hons)

Journals

Year	Citation
2022	Ebert, L. M., Vandyke, K., Johan, M. Z., DeNichilo, M., Tan, L. Y., Myo Min, K. K., . . . Bonder, C. S. (2022). Desmoglein-2 expression is an independent predictor of poor prognosis patients with multiple myeloma. Molecular Oncology, 16(6), 1221-1240. DOI Scopus4 WoS4 Europe PMC2
2021	Opperman, K. S., Vandyke, K., Psaltis, P. J., Noll, J. E., & Zannettino, A. C. W. (2021). Macrophages in multiple myeloma: key roles and therapeutic strategies. Cancer and Metastasis Reviews, 40(1), 273-284. DOI Scopus6 WoS6 Europe PMC2
2021	Vandyke, K. (2021). Seed and soil revisited in multiple myeloma.. Blood, 137(17), 2282-2283. DOI
2020	Friend, N., Noll, J. E., Opperman, K. S., Clark, K. C., Mrozik, K. M., Vandyke, K., . . . Zannettino, A. C. W. (2020). GLIPR1 expression is reduced in multiple myeloma but is not a tumour suppressor in mice.. PLoS One, 15(1), e0228408. DOI WoS2 Europe PMC1
2020	Cheong, C. M., Mrozik, K. M., Hewett, D. R., Bell, E., Panagopoulos, V., Noll, J. E., . . . Vandyke, K. (2020). Twist-1 is upregulated by NSD2 and contributes to tumour dissemination and an epithelial-mesenchymal transition-like gene expression signature in t(4;14)-positive multiple myeloma. Cancer letters, 475, 99-108. DOI Scopus14 WoS14 Europe PMC7
2020	Mrozik, K. M., Cheong, C. M., Hewett, D. R., Noll, J. E., Opperman, K. S., Adwal, A., . . . Zannettino, A. C. W. (2020). LCRF-0006, a small molecule mimetic of the N-cadherin antagonist peptide ADH-1, synergistically increases multiple myeloma response to bortezomib.. FASEB Bioadv, 2(6), 339-353. DOI Scopus2 Europe PMC2
2020	Clark, K. C., Hewett, D. R., Panagopoulos, V., Plakhova, N., Opperman, K. S., Bradey, A. L., . . . Zannettino, A. C. W. (2020). Targeted disruption of bone marrow stromal cell-derived Gremlin1 limits multiple myeloma disease progression in vivo. Cancers, 12(8), 2149-1-2149-20. DOI Scopus3 WoS2 Europe PMC1
2020	Friend, N. L., Hewett, D. R., Panagopoulos, V., Noll, J. E., Vandyke, K., Mrozik, K. M., . . . Zannettino, A. C. W. (2020). Characterization of the role of Samsn1 loss in multiple myeloma development.. FASEB Bioadv, 2(9), 554-572. DOI Scopus1 Europe PMC1
2020	Zeissig, M. N., Hewett, D. R., Panagopoulos, V., Mrozik, K. M., To, L. B., Croucher, P. I., . . . Vandyke, K. (2020). Expression of the chemokine receptor CCR1 promotes the dissemination of multiple myeloma plasma cells in vivo. Haematologica, 106(12), 3176-3187. DOI Scopus4 WoS5 Europe PMC2
2020	Zeissig, M. N., Zannettino, A. C. W., & Vandyke, K. (2020). Tumour dissemination in multiple myeloma disease progression and relapse: A potential therapeutic target in high-risk myeloma. Cancers, 12(12), 1-20. DOI Scopus4 WoS4 Europe PMC4
2019	Khoo, W., Ledergor, G., Weiner, A., Roden, D., Terry, R., McDonald, M., . . . Croucher, P. (2019). A niche-dependent myeloid transcriptome signature defines dormant myeloma cells. Blood, 134(1), 30-43. DOI Scopus61 WoS58 Europe PMC39
2019	Opperman, K. S., Vandyke, K., Clark, K. C., Coulter, E. A., Hewett, D. R., Mrozik, K. M., . . . Zannettino, A. C. (2019). Clodronate-liposome mediated macrophage depletion abrogates multiple myeloma tumor establishment in vivo. Neoplasia, 21(8), 777-787. DOI Scopus35 WoS32 Europe PMC20
2018	Mrozik, K., Blaschuk, O., Cheong, C., Zannettino, A., & Vandyke, K. (2018). N-cadherin in cancer metastasis, its emerging role in haematological malignancies and potential as a therapeutic target in cancer. BMC Cancer, 18(1), 1-16. DOI Scopus136 WoS138 Europe PMC81
2017	Hemming, S., Cakouros, D., Codrington, J., Vandyke, K., Arthur, A., Zannettino, A., & Gronthos, S. (2017). EZH2 deletion in early mesenchyme compromises postnatal bone microarchitecture & structural integrity and accelerates remodeling. FASEB Journal, 31(3), 1011-1027. DOI Scopus41 WoS41 Europe PMC27
2017	Vuckovic, S., Vandyke, K., Rickards, D., McCauley Winter, P., Brown, S., Mitchell, T., . . . Hutchinson, A. (2017). The cationic small molecule GW4869 is cytotoxic to high phosphatidylserine-expressing myeloma cells. British Journal of Haematology, 177(3), 423-440. DOI Scopus17 WoS17 Europe PMC11
2017	Wallington-Beddoe, C., Bennett, M., Vandyke, K., Davies, L., Zebol, J., Moretti, P., . . . Pitson, S. (2017). Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress. Oncotarget, 8(27), 43602-43616. DOI Scopus32 WoS31 Europe PMC19
2017	Vandyke, K., Zeissig, M., Hewett, D., Martin, S., Mrozik, K., Cheong, C., . . . Zannettino, A. (2017). HIF-2α promotes dissemination of plasma cells in multiple myeloma by regulating CXCL12/CXCR4 and CCR1. Cancer Research, 77(20), 5452-5463. DOI Scopus36 WoS36 Europe PMC18
2017	Hewett, D., Vandyke, K., Lawrence, D., Friend, N., Noll, J., Geoghegan, J., . . . Zannettino, A. (2017). DNA barcoding reveals habitual clonal dominance of myeloma plasma cells in the bone marrow microenvironment. Neoplasia : An International Journal for Oncology Research, 19(12), 972-981. DOI Scopus12 WoS11 Europe PMC8
2016	Hemming, S., Cakouros, D., Vandyke, K., Davis, M., Zannettino, A., & Gronthos, S. (2016). Identification of novel EZH2 targets regulating osteogenic differentiation in mesenchymal stem cells. Stem Cells and Development, 25(12), 909-921. DOI Scopus47 WoS47 Europe PMC30
2016	Ng, J., Hynes, K., White, G., Sivanathan, K., Vandyke, K., Bartold, P., & Gronthos, S. (2016). Immunomodulatory properties of induced pluripotent stem cell-derived mesenchymal cells. Journal of Cellular Biochemistry, 117(12), 2844-2853. DOI Scopus26 WoS27 Europe PMC23
2015	Cheong, C., Chow, A., Fitter, S., Hewett, D., Martin, S., Williams, S., . . . Vandyke, K. (2015). Tetraspanin 7 (TSPAN7) expression is upregulated in multiple myeloma patients and inhibits myeloma tumour development in vivo. Experimental Cell Research, 332(1), 24-38. DOI Scopus23 WoS24 Europe PMC17
2015	Mrozik, K., Cheong, C., Hewett, D., Chow, A., Blaschuk, O., Zannettino, A., & Vandyke, K. (2015). Therapeutic targeting of N-cadherin is an effective treatment for multiple myeloma. British Journal of Haematology, 171(3), 387-399. DOI Scopus22 WoS20 Europe PMC17
2015	Noll, J., Vandyke, K., Hewett, D., Mrozik, K., Bala, R., Williams, S., . . . Zannettino, A. (2015). PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma. Journal of Hematology and Oncology, 8(1), 106-1-106-16. DOI Scopus21 WoS22 Europe PMC16
2015	Gan, Z., Fitter, S., Vandyke, K., To, L., Zannettino, A., & Martin, S. (2015). The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma. European Journal of Haematology, 94(4), 343-354. DOI Scopus29 WoS26 Europe PMC19
2014	Noll, J., Hewett, D., Williams, S., Vandyke, K., Kok, C., To, L., & Zannettino, A. (2014). SAMSN1 is a tumor suppressor gene in multiple myeloma. Neoplasia, 16(7), 572-585. DOI Scopus31 WoS31 Europe PMC27
2014	Ahmed, F., Dutta, N., Zannettino, A., Vandyke, K., & Choudhury, N. (2014). Engineering interaction between bone marrow derived endothelial cells and electrospun surfaces for artificial vascular graft applications. Biomacromolecules, 15(4), 1276-1287. DOI Scopus15 WoS14 Europe PMC6
2013	Vandyke, K., Chow, A., Williams, S., To, L., & Zannettino, A. (2013). Circulating N-cadherin levels are a negative prognostic indicator in patients with multiple myeloma. British Journal of Haematology, 161(4), 499-507. DOI Scopus15 WoS18 Europe PMC12
2013	Arthur, A., Panagopoulos, R., Cooper, L., Menicanin, D., Parkinson, I., Codrington, J., . . . Gronthos, S. (2013). EphB4 enhances the process of endochondral ossification and inhibits remodeling during bone fracture repair. Journal of Bone and Mineral Research, 28(4), 926-935. DOI Scopus37 WoS35 Europe PMC25
2013	Vandyke, K., Fitter, S., Drew, J., Fukumoto, S., Schultz, C., Sims, N., . . . Zannettino, A. (2013). Prospective histomorphometric and DXA evaluation of bone remodeling in imatinib-treated CML patients: Evidence for site-specific skeletal effects. Journal of Clinical Endocrinology and Metabolism, 98(1), 67-76. DOI Scopus20 WoS18 Europe PMC14
2012	Fitter, S., Vandyke, K., Gronthos, S., & Zannettino, A. (2012). Suppression of PDGF-induced PI3 kinase activity by imatinib promotes adipogenesis and adiponectin secretion. Journal of Molecular Endocrinology, 48(3), 229-240. DOI Scopus45 WoS40 Europe PMC39
2011	Vandyke, K., Fitter, S., & Zannettino, A. (2011). The tyrosine kinase inhibitor dasatinib (SPRYCEL) inhibits chondrocyte activity and proliferation. Blood Cancer Journal, 1(2), E2. DOI Scopus21 WoS20 Europe PMC8
2010	Vandyke, K., Dewar, A., Diamond, P., Fitter, S., Schultz, C., Sims, N., & Zannettino, A. (2010). The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo. Journal of Bone and Mineral Research, 25(8), 1759-1770. DOI Scopus74 WoS69 Europe PMC53
2010	Fitter, S., Vandyke, K., Schultz, C., White, D., Hughes, T., & Zannettino, A. (2010). Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: A mechanism for improved insulin sensitivity in Type 2 diabetic CML patients?. Journal of Clinical Endocrinology and Metabolism, 95(8), 3763-3767. DOI Scopus43 WoS40 Europe PMC35
2010	Vandyke, K., Fitter, S., Dewar, A., Hughes, T., & Zannettino, A. (2010). Dysregulation of bone remodeling by imatinib mesylate. Blood, 115(4), 766-774. DOI Scopus108 WoS99 Europe PMC71
2009	Vandyke, K., Dewar, A., Menicanin, D., To, L., Hughes, T., Zannettino, A., & Fitter, S. (2009). Imatinib mesylate causes growth plate closure in vivo. Leukemia, 23(11), 2155-2159. DOI Scopus33 WoS32 Europe PMC30
2009	Vandyke, K., Dewar, A., Farrugia, A., Fitter, S., To, B., Hughes, T., & Zannettino, A. (2009). Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis. Leukemia, 23(5), 994-997. DOI Scopus47 WoS46 Europe PMC33
2007	Vandyke, K., White, M. Y., Nguyen-Khuong, T., Ow, K., Luk, S. C. W., Kingsley, E. A., . . . Russell, P. J. (2007). Plant-derived MINA-05 inhibits human prostate cancer proliferation in vitro and lymph node spread in vivo. Neoplasia, 9(4), 322-331. DOI Scopus8 WoS8 Europe PMC6
2007	Vandyke, K., Jackson, P., Rowe, A., Russell, P. J., & Blair, J. M. (2007). Androgen decreases osteoprotegerin expression in prostate cancer cells. Prostate Cancer and Prostatic Diseases, 10(2), 160-166. DOI Scopus2 WoS3 Europe PMC1

Conference Papers

Year	Citation
2017	Zeissig, M. N., Hewett, D. R., Martin, S., Mrozik, K. M., Cheong, C. M., Diamond, P., . . . Zannettino, A. C. W. (2017). HIF-2 alpha Upregulates CCR1 to Promote Dissemination of Plasma Cells in Multiple Myeloma. In BLOOD Vol. 130 (pp. 2 pages). Atlanta, GA: AMER SOC HEMATOLOGY.
2014	Vandyke, K., Mrozik, K. M., Cheong, C. M., Chow, A. W. S., Kok, C. H., Blaschuk, O., . . . Zannettino, A. C. W. (2014). Identification of an Epithelial-to-Mesenchymal Transition (EMT)-like Programme in t(4;14)-Positive Multiple Myeloma Reveals Novel Targets for Therapeutic Intervention. In BLOOD Vol. 124 (pp. 3 pages). San Francisco, CA: AMER SOC HEMATOLOGY. WoS1
2013	Noll, J., Williams, S., Vandyke, K., Kok, C., & Zannettino, A. (2013). IDENTIFICATION AND CHARACTERISATION OF THE ROLE OF SAMSN1 GENE EXPRESSION IN A MURINE MODEL OF MYELOMA AND MYELOMA PATIENTS. In HAEMATOLOGICA Vol. 98 (pp. 316). FERRATA STORTI FOUNDATION.
2008	Vandyke, K., Dewar, A., Diamond, P., Fitter, S., Farrugia, A. N., To, L. B., . . . Zannettino, A. C. W. (2008). Dasatinib (Sprycel (TM)) Inhibits Oteoclast Activity in Vitro and in Vivo Via a C-Fms-Dependent and C-Src-Independent Mechanism. In BLOOD Vol. 112 (pp. 1102-1103). San Francisco, CA: AMER SOC HEMATOLOGY.

Conference Items

Year	Citation
2019	Opperman, K., Vandyke, K., Psaltis, P., Croucher, P., Noll, J., & Zannettino, A. (2019). Macrophages as a potential therapeutic target: Clodronate-liposome treatment inhibits multiple myeloma tumour establishment in vivo. Poster session presented at the meeting of CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG MEDIA GROUP, LP. DOI
2019	Zeissig, M. N., Hewett, D. R., Mrozik, K. M., Panagopoulos, V., Engelhardt, M., To, L. B., . . . Vandyke, K. (2019). Therapeutic Targeting of CCR1 to Prevent Dissemination of Multiple Myeloma Plasma Cells. Poster session presented at the meeting of BLOOD. Orlando, FL: AMER SOC HEMATOLOGY. DOI
2008	Vandyke, K., Dewar, A. L., Davis, A. N., Fiuer, S., Hughes, T. P., To, L. B., & Zannettino, A. C. W. (2008). The tyrosine kinase inhibitor dasatinib decreases osteoclast formation and activity in vitro. Poster session presented at the meeting of 30th Annual Meeting of the American Society for Bone and Mineral Research, as published in Journal of Bone and Mineral Research. Montreal, Canada: Wiley. DOI

Grants
Date	Role	Grant	Funding Body	Amount
2021-2023	CIA	Cancer Australia Priority-driven Young Investigator Grant	Cancer Australia/Cure Cancer Australia/Snowdome Foundation	AUD$198,813
2019-2022	CoI	Strategic Ecosystem Research Partnerships	Leukaemia Foundation	AUD$596,198
2019 - 2021	CIA	Cancer Australia Priority-driven Young Investigator Grant	Cancer Australia/Cure Cancer Australia/Leukaemia Foundation	AUD$198,596
2017-2018	CIA	Cancer Australia Priority-driven Young Investigator Grant	Cure Cancer Australia	AUD$199,454
2016	CIA	Project Grant	Royal Adelaide Hospital Contributing Haematologists' Committee	AUD$25,000
2016	CIE	Project Grant	Royal Adelaide Hospital Research Fund	AUD$50,000

Fellowships
Date	Title	Funding Body	Amount
2018-2021	Beat Cancer Early Career Cancer Research Fellowship	Cancer Council SA	AUD$240,000
2013-2015	Mary Overton Early Career Fellowship	Royal Adelaide Hospital	AUD$252,000
2013-2015	Veronika Sacco Early Career Fellowship	Florey Medical Research Foundation	AUD$222,003
2011	MMRF Research Fellow Award	Multiple Myeloma Research Foundation (USA)	AUD$74,146

Current Higher Degree by Research Supervision (University of Adelaide)

Date	Role	Research Topic	Program	Degree Type	Student Load	Student Name
2022	Co-Supervisor	Lipidomic and metabolomic profiling of the bone marrow microenvironment to understand multiple myeloma disease development	Doctor of Philosophy	Doctorate	Full Time	Miss Mackenzie Rose Skinner
2020	Co-Supervisor	Identification of novel mechanisms that drive the dissemination of multiple myeloma tumour cells	Doctor of Philosophy	Doctorate	Full Time	Miss Hayley Bridget Parkinson
2020	Co-Supervisor	Changes in the bone marrow microenvironment with progression to multiple myeloma	Doctor of Philosophy	Doctorate	Full Time	Miss Laura Joy Trainor
2020	Principal Supervisor	Development and assessment of novel drug delivery strategies to improve the treatment of multiple myeloma	Doctor of Philosophy	Doctorate	Full Time	Ms Sadia Munir
2019	Co-Supervisor	The Yin and Yang of Myeloma Development: The Role of the Bone Marrow Microenvironment in Plasma Cell Dormancy and Activation	Doctor of Philosophy	Doctorate	Full Time	Miss Natalya Plakhova

Past Higher Degree by Research Supervision (University of Adelaide)

Date	Role	Research Topic	Program	Degree Type	Student Load	Student Name
2019 - 2021	Co-Supervisor	Macrophages, Myeloma, Mouse Models and Methodologies	Doctor of Philosophy	Doctorate	Full Time	Mrs Khatora Shanae Opperman
2017 - 2020	Principal Supervisor	CCR1 as a Therapeutic Target in Multiple Myeloma: Preventing Tumour Dissemination and Therapeutic Resistance	Doctor of Philosophy	Doctorate	Full Time	Miss Mara Natasha Zeissig
2013 - 2017	Co-Supervisor	The Role of TWIST1 in Multiple Myeloma	Doctor of Philosophy	Doctorate	Full Time	Miss Chee Man Cheong
2012 - 2018	Co-Supervisor	N-cadherin: Regulation, Role and Therapeutic Targeting in Multiple Myeloma	Doctor of Philosophy	Doctorate	Full Time	Mr Krzysztof Mrozik

Committee Memberships

Date	Role	Committee	Institution	Country
2015 - ongoing	Member	Women's and Children's Hospital Foundation Research Grants Committee
2014 - ongoing	Member	Australian Society for Medical Research SA Committee

Memberships

Date	Role	Membership	Country
2021 - ongoing	Member	International Myeloma Society	United States
2019 - ongoing	Member	Australasian Leukaemia and Lymphoma Group	Australia
2015 - ongoing		Haematology Society of Australia and New Zealand
2014 - ongoing	Member	Australian Society for Medical Research

Position: Research Fellow (B) (with PhD)
Phone: 81284694
Email: kate.vandyke@adelaide.edu.au
Campus: North Terrace
Building: SAHMRI - South, floor 5
Org Unit: Medical Sciences